Home »
INDIANAPOLIS, Nov. 9, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company’s (NYSE: LLY) investigational neutralizing […]
Read more
WEST CHESTER, Pa., November 10, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring […]
Read more
SARASOTA, Fla. and NOVATO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development […]
Read more
TÜBINGEN, Germany / BOSTON, USA – October 23, 2020 — CureVac NV (Nasdaq: CVAC), a biopharmaceutical company developing a new class of drugs based on […]
Read more
INDIANAPOLIS, Oct. 12, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) announced today new efficacy and safety data from the Phase 2 SERENITY study evaluating mirikizumab in patients […]
Read more
LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), Bausch + Lomb, a leading global eye health […]
Read more
NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) […]
Read more
(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian […]
Read more
(HealthDay)—A considerable proportion of patients with lung cancer are prescribed medications that prolong the corrected QT (QTc) interval, limiting their eligibility for clinical trials, according […]
Read more
As much as two fifths (43%) of antibiotic prescriptions in the United States could be inappropriate, warn researchers in a study published by The BMJ […]
Read more